Evidence map›Paper›PMID 42335239›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Protein-enhanced small molecule disruptors of ordered membrane domains.

Katherine M Stefanski, Geoffrey C Li, Dustin D Luu, Kelvin K Fosu, Eduardo Guadarrama, James M Hutchison, Nilabh Saksena, Yelyzaveta Zuy, Alexander J Fisch, Thomas P Hasaka and 5 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Katherine M StefanskiDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.ORCID 0000-0003-3007-0598
Geoffrey C LiDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.ORCID 0000-0001-5035-5916
Dustin D LuuSchool of Molecular Sciences, Arizona State University, Tempe, AZ 85287.ORCID 0000-0003-3464-160X
Kelvin K FosuSchool of Molecular Sciences, Arizona State University, Tempe, AZ 85287.ORCID 0000-0002-6299-2354
Eduardo GuadarramaDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
James M HutchisonDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.
Nilabh SaksenaDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.ORCID 0009-0001-9374-5006
Yelyzaveta ZuyDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.ORCID 0009-0002-3085-7083
Alexander J FischDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.
Thomas P HasakaDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.ORCID 0009-0003-6522-323X
Joshua A BauerDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.
Alfred L GeorgeDepartment of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.ORCID 0000-0002-3993-966X
Anne K KenworthyCenter for Membrane and Cell Physiology, University of Virginia School of Medicine, Charlottesville, VA 22908.ORCID 0000-0001-6567-9059
Wade D Van HornSchool of Molecular Sciences, Arizona State University, Tempe, AZ 85287.ORCID 0000-0002-2493-5578
Charles R SandersDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37240.ORCID 0000-0003-2046-2862

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
Decrypting Variants of Uncertain Significance in Long-QT SyndromeR01HL122010 · NHLBI · VANDERBILT UNIVERSITY · PI GEORGE, ALFRED L., SANDERS, CHARLES R · 2014 to 2025
$15.5M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Folding, Misfolding, and Function of PMP22R01NS095989 · NINDS · VANDERBILT UNIVERSITY · PI Bruce D Carter, CHARLES R SANDERS · 2016 to 2026
$4.6M
Molecular Mechanisms and Regulation Networks of TRPM8 - Renewal - 1R35GM141933 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI Wade D. Van Horn · 2021 to 2026
$2.5M
Understanding human TRPV1 polymodal activationR01NS119505 · NINDS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI Wade D. Van Horn · 2022 to 2026
$1.9M
Cancer Pharmacologist and HTS ScientistR50CA211206 · NCI · VANDERBILT UNIVERSITY · PI Joshua A. Bauer · 2016 to 2026
$1.8M
Small Molecule Tools for Modulating Membrane RaftsR01GM138493 · NIGMS · UNIVERSITY OF VIRGINIA · PI KENWORTHY, ANNE K, SANDERS, CHARLES R · 2020 to 2022
$1.2M
American Heart Association (AHA) 26POST1542927HHS | NIH | National Cancer Institute (NCI) CA68485HHS | NIH | National Cancer Institute (NCI) P30 CA68485HHS | NIH | National Eye Institute (NEI) EY08126HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL122010HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK20593HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK58404HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK59637HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM138493HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM141933HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM151766HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS095989HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS119505HHS | NIH (NIH) 1S10OD021630HHS | NIH (NIH) S10OD034362HHS | NIH (NIH) UL1TR00044NCATS NIH HHS UL1 TR000445NCI NIH HHS P30 CA068485NCI NIH HHS R50 CA211206NEI NIH HHS P30 EY008126NHLBI NIH HHS R01 HL122010NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIGMS NIH HHS F32 GM151766NIGMS NIH HHS R01 GM138493NIGMS NIH HHS R35 GM141933NIH HHS S10 OD021630NIH HHS S10 OD034362NINDS NIH HHS R01 NS095989NINDS NIH HHS R01 NS119505
6 · The paper itself

Abstract

Membrane order and fluidity influence many biological processes. However, tools to manipulate membranes under physiological conditions have been limited. In the process of high-throughput screening for molecules that shift the phase partitioning between ordered and disordered membrane phases of the tetraspan membrane protein peripheral myelin protein 22 (PMP22), we identified two chemically similar compounds, VU0615562 and VU0619195, that shift PMP22 toward the disordered phase and destabilize the "lipid raft"-like ordered phase. Follow-up experiments showed that this latter activity is, counterintuitively, enhanced by the presence of PMP22, which normally stabilizes the ordered phase. Biophysical studies indicate that these compounds reduce raft stability through a mechanism that involves both direct interactions with proteins and the disruption of lipid packing. We further observed that acute treatment of live cells with VU0619195 modulated membrane fluidity and TRPM8 channel function while both compounds altered KCNQ1 channel activity, providing examples of practical applications for these compounds. These protein-enhanced raft modulators reveal distinct lipid and protein-based forces that destabilize membrane order and may be useful as pharmacological tools for manipulating and probing the biological roles of ordered membrane domains in cells.

Indexed as

Membrane MicrodomainsSmall Molecule LibrariesHigh-Throughput Screening AssaysHumansMembrane FluiditySmall Molecule LibrariesGPMVshigh-throughput screenlipid raftmembrane fluiditysmall molecule

Identifiers

PMID42335239
PMCPMC13293285

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.